Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 3, 2012, Pages 225-233

  Lehman, Dara A ^a   Wamalwa, Dalton C ^b   McCoy, Connor O ^a   Matsen, Frederick A ^a   Langat, Agnes ^b   Chohan, Bhavna H ^b,c   Benki Nugent, Sarah ^c   Custers Allen, Rebecca ^d   Bushman, Frederic D ^d   John Stewart, Grace C ^c   Overbaugh, Julie ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

HAART; HIV; infants; nevirapine; resistance; treatment failure

Indexed keywords

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ALLELE; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFANT; INFANT DISEASE; MUTATION; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; KENYA; MUTATION; NEVIRAPINE; PREGNANCY; TREATMENT FAILURE;

EID: 84864316421     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182515730     Document Type: Article

References (36)

1. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
2. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217-228.
3. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-tochild transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-868.
4. World Health Organization. Anitretroviral drugs for treating pregnant women and preventing HIV infection in infants, 2010 version. Available at: http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index. html. Accessed August 2011.
5. McIntyre J. Use of antiretrovirals during pregnancy and breastfeeding in low-income and middle-income countries. Curr Opin HIV AIDS. 2010;5:48-53.
6. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;14:F111-F115.
7. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15: 1951-1957.
8. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002;4:59-63.
9. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192:16-23.
10. Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010;363: 1510-1520.
11. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135-147.
12. Flys Tamara S, Donnell D, Mwatha A, et al. Persistence of K103NContaining HIV-1 Variants after Single-Dose Nevirapine for Prevention of HIV-1 Mother-to-Child Transmission. J Infect Dis. 2007;195: 711-715.
13. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005; 192:24-29.
14. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: Towards universal access, 2010 version. Available at: http://www.who.int/hiv/pub/paediatric/infants2010/en/index.html. Accessed August 2011.
15. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010;304:1082-1090.
16. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011;305:1327-1335.
17. Gianella S, Richman DD. Minority variants of drug-resistant HIV. J Infect Dis. 2010;202:657-666.
18. Standford University HIV drug resistance database. Available at: http://hivdb.stanford.edu/index.html. Accessed August 2011.
19. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci USA. 2011;108:9202-9207.
20. Newell ML, Coovadia H, Cortina-Borja M, et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet. 2004;364:1236-1243.
21. Richardson BA, Mbori-Ngacha D, Lavreys L, et al. Comparison of human immunodeficiency virus type 1 viral loads in Kenyan women, men, and infants during primary and early infection. J Virol. 2003;77:7120-7123.
22. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
23. Macleod IJ, Rowley CF, Thior I, et al. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapinecontaining ART. J Clin Virol. 2010;48:162-167.
24. Hunt GM, Coovadia A, Abrams EJ, et al. HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011;25:1461-1469.
25. Chohan BH, Emery S, Wamalwa D, et al. Evaluation of a single round polymerase chain reaction assay using dried blood spots for diagnosis of HIV-1 infection in infants in an African setting. BMC Pediatr. 2011;11:18.
26. Emery S, Bodrug S, Richardson BA, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol. 2000;38:2688-2695.
27. Lehman DA, Chung MH, Mabuka JM, et al. Lower risk of resistance after short-course HAART compared to zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission. J Acquir Immune Defic Syndr. 2009;51:522-529.
28. Hedskog C, Mild M, Jernberg J, et al. Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS ONE. 2010;5:e11345.
29. Svarovskaia ES, Moser MJ, Bae AS, et al. MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samples. J Clin Microbiol. 2006;44:4237-4241.
30. Poss M, Overbaugh J. Variants from the diverse virus population identified at seroconversion of a clade A human immunodeficiency virus type 1-infected woman have distinct biological properties. J Virol. 1999;73: 5255-5264.
31. Rice P, Longden I, Bleasby A. EMBOSS: The European Molecular Biology Software Suite. Trends Genet. 2000;16:276-277.
32. Moorthy A, Gupta A, Bhosale R, et al. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. PLoS ONE. 2009;4:e4096.
33. Martinson NA, Morris L, Gray G, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007;44:148-153.
34. Delobel P, Saliou A, Nicot F, et al. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS ONE. 2011;6:e21655.
35. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapinebased antiretroviral therapy. N Engl J Med. 2004;351:229-240.
36. Eshleman SH, Guay LA, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr. 2005;40:24-29.